FI117788B - Dietlivsmedel innehållande fettsyror med medellånga kedjor samt användning av detta - Google Patents
Dietlivsmedel innehållande fettsyror med medellånga kedjor samt användning av detta Download PDFInfo
- Publication number
- FI117788B FI117788B FI952465A FI952465A FI117788B FI 117788 B FI117788 B FI 117788B FI 952465 A FI952465 A FI 952465A FI 952465 A FI952465 A FI 952465A FI 117788 B FI117788 B FI 117788B
- Authority
- FI
- Finland
- Prior art keywords
- dietary
- acid
- alpha
- fatty acids
- fat
- Prior art date
Links
- 235000005911 diet Nutrition 0.000 title claims abstract description 38
- 235000013305 food Nutrition 0.000 title claims abstract description 35
- 230000000378 dietary effect Effects 0.000 title claims abstract description 34
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 9
- 239000000194 fatty acid Substances 0.000 title claims abstract description 8
- 229930195729 fatty acid Natural products 0.000 title claims abstract description 8
- 150000004665 fatty acids Chemical class 0.000 title claims abstract description 8
- 235000019197 fats Nutrition 0.000 claims abstract description 27
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 24
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 12
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 12
- 229960004232 linoleic acid Drugs 0.000 claims abstract description 9
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 14
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 13
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 13
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 13
- 229960002733 gamolenic acid Drugs 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 239000012071 phase Substances 0.000 claims description 13
- 206010025476 Malabsorption Diseases 0.000 claims description 12
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 9
- 229960000304 folic acid Drugs 0.000 claims description 8
- 239000011724 folic acid Substances 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 7
- 230000007812 deficiency Effects 0.000 claims description 7
- 235000019152 folic acid Nutrition 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 239000003613 bile acid Substances 0.000 claims description 6
- 229930003779 Vitamin B12 Natural products 0.000 claims description 5
- 239000008346 aqueous phase Substances 0.000 claims description 5
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- 235000019163 vitamin B12 Nutrition 0.000 claims description 5
- 239000011715 vitamin B12 Substances 0.000 claims description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- 235000019166 vitamin D Nutrition 0.000 claims description 4
- 239000011710 vitamin D Substances 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 102000004882 Lipase Human genes 0.000 claims description 3
- 108090001060 Lipase Proteins 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 3
- 235000013734 beta-carotene Nutrition 0.000 claims description 3
- 239000011648 beta-carotene Substances 0.000 claims description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 3
- 229960002747 betacarotene Drugs 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 230000002779 inactivation Effects 0.000 claims description 3
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 3
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 claims description 2
- 206010060749 Type I hyperlipidaemia Diseases 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 238000013110 gastrectomy Methods 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000018501 Lymphatic disease Diseases 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000001130 gallstones Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000018555 lymphatic system disease Diseases 0.000 claims 1
- 230000004203 pancreatic function Effects 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 description 12
- 208000015943 Coeliac disease Diseases 0.000 description 10
- 235000013310 margarine Nutrition 0.000 description 7
- 239000003264 margarine Substances 0.000 description 7
- 150000004668 long chain fatty acids Chemical class 0.000 description 6
- 108010068370 Glutens Proteins 0.000 description 5
- 235000004626 essential fatty acids Nutrition 0.000 description 5
- 235000021312 gluten Nutrition 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000028774 intestinal disease Diseases 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 235000019485 Safflower oil Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000013367 dietary fats Nutrition 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 235000021388 linseed oil Nutrition 0.000 description 3
- 239000000944 linseed oil Substances 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000021313 oleic acid Nutrition 0.000 description 3
- 235000005713 safflower oil Nutrition 0.000 description 3
- 239000003813 safflower oil Substances 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 102100034544 Acyl-CoA 6-desaturase Human genes 0.000 description 2
- 240000004355 Borago officinalis Species 0.000 description 2
- 235000007689 Borago officinalis Nutrition 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- 108010037138 Linoleoyl-CoA Desaturase Proteins 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000014594 pastries Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- VMSLCPKYRPDHLN-UHFFFAOYSA-N (R)-Humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-UHFFFAOYSA-N 0.000 description 1
- 206010002064 Anaemia macrocytic Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 208000017283 Bile Duct disease Diseases 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000006123 Myiasis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 208000035467 Pancreatic insufficiency Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000027207 Whipple disease Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000012820 baking ingredients and mixes Nutrition 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000006171 gluten free diet Nutrition 0.000 description 1
- 235000020884 gluten-free diet Nutrition 0.000 description 1
- 230000000215 hyperchromic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 201000006437 macrocytic anemia Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0056—Spread compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Seeds, Soups, And Other Foods (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Edible Oils And Fats (AREA)
Claims (14)
1. Dietlivsmedel, kännetecknat av att dess fettfas innehäller 5 (a) 70-90 % fettsyror med medellänga kedjor, (b) alfa-linolsyra och (c) alfa-linolensyra.
2. Dietlivsmedel enligt patentkrav 1, känne tecknat av att fettfasen dessutom innehäller gamma- 10 linolensyra.
3. Dietlivsmedel enligt patentkrav 1 eller 2, kännetecknat av att halten av alfa-linolsyra är 5,9 - 13,4 %.
4. Dietlivsmedel enligt nägot av patentkraven 1 - 15 3, kännetecknat av att halten av alfa-linolensyra är 1,4-6,5 %.
5· Dietlivsmedel enligt nägot av patentkraven 1 - 4, kännetecknat av att halten av gamma-linolensyra är 0,1-2,5 % .
6. Dietlivsmedel enligt nägot av patentkraven 1 - 5, kännetecknat av att halten av mättade fettsyror • ♦ · : med länga kedjor är högst 4 %. • · · *.ϊ·* 7. Dietlivsmedel enligt nägot av patentkraven 1 - „1;* 6, kännetecknat av att fettfasens komposition är ί#*.Σ 25 följande: : Fettsyror med medellänga kedjor 70 - 90 % ··* · ·*·*· Mättade fettsyror med länga kedjor 0,9 - 4,9 % « Alfa-linolsyra 5,9 - 13,4 % . Alfa-linolensyra 1,4 - 6,5 % • · · lii 30 Gamma-linolensyra 0,1 - 2,5 % **:*’ Oljesyra 1,7-3,6% ··· • · •e,···' ··· *:**i 8. Dietlivsmedel enligt nägot av patentkraven 1 - I;. 7, kännetecknat av att fettfasens komposition är ‘lii 35 följande: • · ♦ · ♦ ♦♦ 117788 Fettsyror med medellänga kedjor 80 % Mättade fettsyror med länga kedjor cirka 1,6 % Alfa-linolsyra cirka 9 % Alfa-linolensyra cirka 5,4 %
5 Gamma-linolensyra cirka 1,8 % Oljesyra cirka 2,2 %
9. Dietlivsmedel enligt nägot av patentkraven 1 -8, kännetecknat av att fettfasen dessutom innehäller 10 emulgeringsmedel, fettlösliga vitaminer, β-karoten och/ eller lecitin. -,
10. Dietlivsmedel enligt patentkrav 9, kännetecknat av att de fettlösliga vitaminerna är A-, D-och/eller E-vitamin.
11. Dietlivsmedel enligt nägot av patentkraven 1 - 10, kännetecknat av att fettfasens andel är cirka 80 % och vattenfasens andel är cirka 20 %.
12. Dietlivsmedel enligt patentkrav 11, kännetecknat av att vattenfasen innehäller C-vitamin, fol- 20 syra och/eller B12-vitamin.
13. Användning av dietlivsmedel enligt nägot av • · ·.· · patentkraven 1-12 för framställning av en produkt för ϊ#ϊ]ϊ näringsterapeutisk behandling av malabsorptionssyndrom. ·;* 14. Användning enligt patentkrav 13, kanne- ···· ;‘.J 25 tecknad av att malabsorptionssyndromet hänför sig tili • · : .·. brist pä gallsyror, nedsatt bukspottkörtelfunktion, kro- .···. nisk bukspottkörtelinf lammation, levercirros, partiell • · · gastrektomi (postgastrektomisyndrom), mekanisk spärr av , koledokus, gallstenar, inaktivering av gallsyror genom in- * * * '•|·* 30 verkan av läkemedel, celiaki, vuxen spru, segslemutsönd- • · *·..* ringssjukdom (cystbukspottkörtelfibros) , typ I hyperlipo- proteinemi (triglycerid-lipasbrist) , morbus Wippel-sjukdom · · ·...: eller lymfaströmstörningar. ··· ···♦ ·*· · φ · • · ·
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4417851 | 1994-05-20 | ||
| DE4417851A DE4417851C1 (de) | 1994-05-20 | 1994-05-20 | Diätetisches Lebensmittel mit mittelkettigen Fettsäuren und dessen Verwendung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI952465A0 FI952465A0 (sv) | 1995-05-19 |
| FI952465A FI952465A (sv) | 1995-11-21 |
| FI117788B true FI117788B (sv) | 2007-02-28 |
Family
ID=6518676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI952465A FI117788B (sv) | 1994-05-20 | 1995-05-19 | Dietlivsmedel innehållande fettsyror med medellånga kedjor samt användning av detta |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0682879B1 (sv) |
| AT (1) | ATE197380T1 (sv) |
| DE (2) | DE4417851C1 (sv) |
| DK (1) | DK0682879T3 (sv) |
| ES (1) | ES2153443T3 (sv) |
| FI (1) | FI117788B (sv) |
| GR (1) | GR3035094T3 (sv) |
| NO (1) | NO312393B1 (sv) |
| PT (1) | PT682879E (sv) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19528461A1 (de) * | 1995-08-03 | 1997-02-06 | Braun Melsungen Ag | Präparat zur Ernährung |
| ES2179156T3 (es) | 1996-11-20 | 2003-01-16 | Nutricia Nv | Composicion nutricional que incluye grasas para el tratamiento del sindrome metabolico. |
| AU6279398A (en) * | 1997-02-21 | 1998-09-09 | Beth Israel Deaconess Medical Center | A novel nutritional therapy which minimizes plasma cholecystokinin (cck) levels |
| US6013665A (en) * | 1997-12-16 | 2000-01-11 | Abbott Laboratories | Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides |
| CA2351469A1 (en) * | 1998-12-15 | 2000-06-22 | Susan Marie Kaup | Method and composition for the maintenance and restitution of gut integrity |
| US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
| DE10254584A1 (de) * | 2002-11-22 | 2004-06-09 | HORST HEIRLER PROJEKTE für Ernährung, Medizin, Ökologie | Verwendung von mittelkettigen Triglyceriden (MCT) zur ernährungsphysiologischen Optimierung des Fettsäurenspektrums in einem diätetischen Lebensmittel für Diabetiker |
| US20050032892A1 (en) * | 2003-08-07 | 2005-02-10 | The Procter & Gamble Company | Compositions, kits, and methods for treating gastrointestinal conditions |
| US7759507B2 (en) * | 2003-09-05 | 2010-07-20 | Abbott Laboratories | Lipid system and methods of use |
| EP1656934A1 (en) * | 2004-11-12 | 2006-05-17 | Cognis IP Management GmbH | Use of physiologically active fatty acids for treating lipodystrophy |
| CA2963341A1 (en) * | 2007-11-06 | 2009-05-14 | University Of Sydney | Use of vitamin d receptor agonists and precursors to treat fibrosis |
| WO2014176394A1 (en) | 2013-04-24 | 2014-10-30 | Salk Institute For Biological Studies | Vitamin d receptor/smad genomic circuit gates fibrotic response |
| WO2019023149A1 (en) | 2017-07-24 | 2019-01-31 | Salk Institute For Biological Studies | USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8205047A (nl) * | 1982-12-30 | 1984-07-16 | Unilever Nv | Vetten geschikt voor gebruik als hardvetcomponenten in margarines en margarinevetmengsels voor in wikkels te verpakken margarines. |
| US4871768A (en) * | 1984-07-12 | 1989-10-03 | New England Deaconess Hospital Corporation | Dietary supplement utilizing ω-3/medium chain trigylceride mixtures |
| EP0466768B2 (en) * | 1989-04-07 | 1999-06-30 | New England Deaconess Hospital Corporation | Short-chain triglycerides |
| CA2012707A1 (en) * | 1989-04-11 | 1990-10-11 | Lawrence P. Klemann | Partially digestible sucrose esters as low calorie fat mimetics |
| JP3102645B2 (ja) * | 1990-10-15 | 2000-10-23 | 雪印乳業株式会社 | 栄養補給用栄養組成物 |
| ES2033193B1 (es) * | 1990-10-30 | 1994-01-16 | Ganadera Union Ind Agro | Mezcla grasa para nutricion infantil y de adultos. |
| JP3098571B2 (ja) * | 1991-06-18 | 2000-10-16 | 花王株式会社 | 経腸栄養剤組成物 |
| JPH05262645A (ja) * | 1992-03-19 | 1993-10-12 | Nippon Oil & Fats Co Ltd | 脂肪乳剤 |
| US5223285A (en) * | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
| US5395629A (en) * | 1992-11-12 | 1995-03-07 | Nestec S.A. | Preparation of butterfat and vegetable butter substitutes |
| DE69420124T2 (de) * | 1993-01-15 | 2000-03-02 | Abbott Laboratories, Abbott Park | Strukturierte lipide |
-
1994
- 1994-05-20 DE DE4417851A patent/DE4417851C1/de not_active Expired - Lifetime
-
1995
- 1995-05-18 EP EP95107610A patent/EP0682879B1/de not_active Expired - Lifetime
- 1995-05-18 PT PT95107610T patent/PT682879E/pt unknown
- 1995-05-18 DE DE59508831T patent/DE59508831D1/de not_active Expired - Lifetime
- 1995-05-18 DK DK95107610T patent/DK0682879T3/da active
- 1995-05-18 AT AT95107610T patent/ATE197380T1/de active
- 1995-05-18 ES ES95107610T patent/ES2153443T3/es not_active Expired - Lifetime
- 1995-05-19 FI FI952465A patent/FI117788B/sv not_active IP Right Cessation
- 1995-05-19 NO NO19951992A patent/NO312393B1/no not_active IP Right Cessation
-
2000
- 2000-12-18 GR GR20000402782T patent/GR3035094T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE59508831D1 (de) | 2000-12-14 |
| PT682879E (pt) | 2001-02-28 |
| ES2153443T3 (es) | 2001-03-01 |
| NO312393B1 (no) | 2002-05-06 |
| DK0682879T3 (da) | 2001-01-15 |
| NO951992L (no) | 1995-11-21 |
| NO951992D0 (no) | 1995-05-19 |
| EP0682879A1 (de) | 1995-11-22 |
| DE4417851C1 (de) | 1995-10-05 |
| EP0682879B1 (de) | 2000-11-08 |
| GR3035094T3 (en) | 2001-03-30 |
| FI952465A (sv) | 1995-11-21 |
| FI952465A0 (sv) | 1995-05-19 |
| ATE197380T1 (de) | 2000-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI117788B (sv) | Dietlivsmedel innehållande fettsyror med medellånga kedjor samt användning av detta | |
| ES2577935T3 (es) | Régimen de alimentación por etapas para lactantes para estimular un desarrollo y crecimiento saludables | |
| JP4391673B2 (ja) | 油脂組成物 | |
| BELL et al. | The new dietary fats in health and disease | |
| CN101360490A (zh) | 具有二十二碳五烯酸的组合物 | |
| US20040076695A1 (en) | EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia | |
| US4690820A (en) | High-caloric, high-fat dietary formula | |
| JPWO2005023021A1 (ja) | ダイエット食品 | |
| NO20110233A1 (no) | Naeringsmiddelsammensetning for a fremme sunn utvikling og vekst | |
| JPH0811048B2 (ja) | 肺疾患患者用栄養製品 | |
| CN103002889B (zh) | Sn‑2‑单酰基甘油和脂质吸收不良 | |
| JP2016535036A (ja) | 消化不良の処置における使用のためのモノアシルグリセロール及び脂溶性栄養素 | |
| EP1964554A1 (en) | Lipid mixture and use thereof for the preparation of a product that is intended for enteral or oral administration | |
| CN106998774A (zh) | 包含人乳低聚糖、多不饱和脂肪酸、核苷酸以及叶黄素的婴儿配方 | |
| JP5296366B2 (ja) | 医薬品用持久力向上剤および持久力向上用医薬品 | |
| JP3544493B2 (ja) | 乳幼児用栄養組成物 | |
| JP2646272B2 (ja) | 乳脂肪を含有する構造化脂質 | |
| JPH05306222A (ja) | 患者の胃腸の完全性および機能を保持するための短鎖脂肪酸含有脂質類の使用 | |
| ES2298224T3 (es) | Aceite vegetal natural concentrado en insaponificable como ingrediente alimenticio. | |
| EP3062786A1 (en) | Monoacylglycerols for use in the treatment of malabsorption having a mechanical basis | |
| JPS6115647A (ja) | 油脂食品 | |
| Goncharova et al. | Enhanced absorption of long-chain polyunsaturated fatty acids following consumption of functional milk formula, pre-digested with immobilized lipase ex vivo, in an exocrine pancreatic insufficient (EPI) pig model | |
| ITMI20101666A1 (it) | Composizione a base di acido docosaesaenoico (dha), nel trattamento della fibrosi cistica e della steatosi epatica non alcolica | |
| US11679091B2 (en) | Lymphatic circulation improving agents | |
| Sharma et al. | Nutritional management of children with cystic fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 117788 Country of ref document: FI |
|
| PC | Transfer of assignment of patent |
Owner name: DR. SCHAER GMBH / SRL. Free format text: DR. SCHAER GMBH / SRL. |
|
| PC | Transfer of assignment of patent |
Owner name: DR. SCHAER AG |
|
| MA | Patent expired |